Status: Recruiting
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Participants needed: 135
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestUpdated: Jun 22, 2026Locations: 14
Eligibility criteria
Patient has signed informed written consent. [+13]
Patient has prior sentinel lymph node removal for the current MCC. [+16]